News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Takeda Pharmaceuticals North America, Inc.'s Actos Has Same Heart Risks as GlaxoSmithKline’s Avandia, Researchers Find
August 25, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Takeda Pharmaceutical Co.’s diabetes drug Actos causes as many heart problems as Avandia, the GlaxoSmithKline Plc pill that had a decline in sales after being linked to higher heart-disease rates, a study found.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
GlaxoSmithKline
Takeda
MORE ON THIS TOPIC
PARTNERED
Where AI Adds Real Value in Clinical Development
May 12, 2025
·
7 min read
·
BioSpace Insights
Drug Development
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
May 8, 2025
·
1 min read
·
Lori Ellis
Gene therapy
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
May 7, 2025
·
4 min read
·
Annalee Armstrong
Cancer
Summit’s Campaign To Conquer Keytruda Nears First Global Phase III Data
May 7, 2025
·
5 min read
·
Nick Paul Taylor